CompletedNot Applicable

Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3

Egypt120 participantsStarted 2020-12-01

Plain-language summary

This study will determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury in chronic kidney disease patients Stage 3 undergoing percutaneous coronary intervention.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Age ≥ 18 years old . Patients under treatment of high dose statin(Atorvastatin (40-80 mg/day) . Glomerular filtration rate=30-59ml/min. Undergoing coronary PCI. Exclusion Criteria: Patients under treatment with febuxostat. Known allergy to febuxostat. High osmolar contrast media during the procedure .

What they're measuring

prevention of CI-AKI

Timeframe: 48-72 hours post contrast

Trial details

NCT IDNCT05264584

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-09-01

View on ClinicalTrials.gov More Chronic Kidney Disease stage3 trials